Iberdomide Drives Effector T Cell Expansion and Increases Immune Activation in Combination with Daratumumab and Dexamethasone in the Multiple Myeloma Patients (IMS 2026) - Sep 11, 2026 - Abstract #PA-231; Pres time: Sep 23, 2026; "Recently, the phase 3 EXCALIBER-RRMM trial demonstrated superior minimal residual disease (MRD) negativity rates with Iber+Dara+Dex versus Bortezomib Dara+Dex. ber functions as the primary immunomodulatory agent driving therapeutic activity in this combination, with Dara inducing CD38+ cell depletion in NK cells and T-cells. Immunomodulatory changes observed in BM that are absent in PB with Dara addition—particularly alterations in central memory T-cells—provide compelling rationale for comprehensive BM tumor microenvironment analysis in future mechanistic studies. These findings support the biological basis for superior MRD negativity observed with triplet therapy in EXCALIBER-RRMM."
Clinical • Combination therapy • IO biomarker • Hematological Malignancies • Multiple Myeloma • Targeted Protein Degradation • CD14 • CD38 • CD69 • CD8 • CRBN
|
|
Adolfo Aleman1; Juliana Ferrucio2; Shriya Desai3; Junia Vieira Dos Santos4; Sidorela Reci3; Kedwin Ventura3; Udo Oppermann5; Sarah Gooding5; Patrick Hagner2; Abstracts S176 23rd International Myeloma Society Annual Meeting September 2026 Chad Bjorklund2; Michael Amatangelo2; Anita Gandhi2; Samir Parekh6; Alessandro Lagana6
|